Previous close | 0.2300 |
Open | 0.2300 |
Bid | 0.1400 |
Ask | 0.3300 |
Strike | 47.50 |
Expiry date | 2025-01-17 |
Day's range | 0.2300 - 0.2300 |
Contract range | N/A |
Volume | |
Open interest | 111 |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.